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TO THE EDITOR
Keratinocytes change markedly as they
differentiate from the basal layer to
spinous, granular, and cornified cells.
This epidermal stratification is tightly
controlled and is essential to maintain
the effective barrier function of the
epidermis (Koster, 2009), but differ-
ences in gene expression and the
controlling transcription factors are
only partly understood. Some insights
into differential gene expression have
been obtained by laser capture micro-
dissection (LCM) or cell separation
methods, but in the case of LCM, only
selected genes were analyzed by real-
time PCR (Percoco et al., 2012). Radoja
et al. (2006) separated basal versus
suprabasal cells by sorting based on b4
integrin expression and profiled genes
using whole-genome arrays. However,
differentiation-specific genes such as
loricrin and filaggrin were enriched
o4-fold in the b4-negative (suprabasal)
fraction. In this study, we have coupled
LCM that generated 4400-fold enrich-
ment in loricrin and filaggrin mRNAs
with whole-genome mRNA arrays to
broadly assess differentiation-related
transcription factors and other gene pro-
ducts in basal versus suprabasal human
epidermis.
We applied LCM to normal human
skin derived from three volunteers in
order to isolate the following three
regions: reticular dermis (as a reference),
basal epidermis, and suprabasal (spinous,
granular, and cornified layers) epidermis
(Supplementary Figure S1 online). We
then extracted RNA from each of these
regions and generated their gene expres-
sion profiles using Affymetrix HGU133
Plus 2.0 arrays (Affymetrix, Santa Clara,
CA) as described (Supplementary
Materials and Methods online).
The transcriptional profiles of the three
captured regions distinctly separated from
each other by principal components ana-
lysis, with minimal deviation between the
three biological replicates. As expected
owing to their vastly different cellular
composition, the reticular dermis samples
were especially far removed from the
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Figure 1. Principal components analysis (PCA) and immunohistochemistry confirm effective separation
of different epidermal regions. (a) PCA of microarray data. The ‘‘whole epidermis’’ data points represent
full epidermis laser capture microdissection performed as part of a separate experiment (Kennedy-Crispin et al.,
2012). (b–h) Immunohistochemical confirmation of transcription factor localization (see Table 1). Immunohisto-
chemistry staining of normal skin samples for the following: (b) CD11c as a negative control for epidermal
staining, (c) pituitary tumor-transforming gene 1 (PTTG1), (d) zinc-finger protein 281 (ZNF281), (e) regulatory
factor X5 (RFX5), (f) Sp4 transcription factor (SP4), (g) aryl hydrocarbon receptor nuclear translocator-like 2
(ARNTL2), and (h) sterol regulatory element–binding transcription factor 2 (SREBF2). Images c–f confirm a basal
layer localization, whereas images g and h confirm a suprabasal localization. Bar¼100mm.
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other two epidermal regions (Figure 1a).
Whole epidermis captured by LCM was
very similar to the suprabasal epidermis
but quite distinct from the basal epider-
mis, highlighting the utility of this
approach to separate out basal from the
suprabasal epidermis. Using cutoffs of
false discovery rate (FDR) o0.01 and
fold change 41.5, we found 286 upre-
gulated and 310 downregulated genes in
the basal versus suprabasal epidermis
(raw data deposited in Gene Expression
Omnibus accession number GSE42114).
Some gene expression changes con-
firmed many expected differences
between the basal and suprabasal epider-
mis (Supplementary Table S1 online, full
list available on request), as well as
between the basal epidermis and reticular
dermis (Supplementary Table S2 online,
full list available on request). For
instance, keratin 5 was increased 7.7-fold
in the basal epidermis, whereas filaggrin
was increased 492.8-fold in the supraba-
sal epidermis (FDR o10 4 for both).
Furthermore, many genes associated with
basal epidermis–resident melanocytes,
such as dopachrome tautomerase and
melan-A, were upregulated in the basal
epidermis (Supplementary Table S1
online). In other words, many of the
genes found to be upregulated in the
basal epidermis will prove to be melano-
cyte-specific, and therefore these differ-
entially expressed gene lists have the
potential to improve our understanding
of melanocyte biology.
Our data led to the identification of
many transcription factors, to our
knowledge, not previously localized in
human skin, including regulatory factor
X5 and sterol regulatory element–
binding transcription factor 2 (SREBF2)
(Table 1, full list in Supplementary Table
S3 online). The preferential localization
of transcription factors to either the
basal or suprabasal epidermis was con-
firmed by immunohistochemical stain-
ing of normal human skin using
antibodies specific to six identified
factors (Figure 1b–h). The discovery of
transcription factors such as those found
in this study has the potential to improve
our mechanistic understanding of how
cells differentiate from the basal to
suprabasal layers of the epidermis. The
functional role of many of these factors
remains to be determined, but several of
them are already known to display skin
phenotypes (either related to pigmenta-
tion (Nagarajan et al., 2009) or differe-
ntiation (Steinmayr et al., 1998)) when
knocked out in mouse models. Com-
bined with our data, this suggests that
these transcription factors have direct,
endogenous functions in epidermal
cells.
By Ingenuity Pathway Analysis,
SREBF2 is predicted to be activated
and to account for the gene expression
changes observed between the supraba-
sal epidermis and the reticular dermis
(bias-corrected z-score¼ 2.603) but not
between the basal epidermis and the
reticular dermis, therefore suggesting
that this transcription factor has a func-
tional role in epidermal differentiation.
This view is supported by the role of
SREBF2 in lipid synthesis (Harris et al.,
1998), which is known to a be a
function of suprabasal keratinocytes. In
addition, SREBF2 has been implicated in
wound healing by mouse studies
(Merath et al., 2011).
We note that our results differ signifi-
cantly from those reported by Radoja
et al. (2006). Of the 596 genes we found
to be differentially regulated between
the basal and suprabasal epidermis, only
72 were found by the Radoja et al.
(2006) study (Supplementary Figure S2
online). Two factors may account for the
observed differences between studies.
First, enrichment of differentiated epi-
dermal layers is higher for LCM meth-
ods. Similar to a previous study in which
loricrin and filaggrin mRNA were
enhanced by 783- and 446-fold, respec-
tively, by LCM (Kennedy-Crispin et al.,
2012), we had 4400-fold enrichment in
the suprabasal versus basal epidermis in
this study. Incomplete cell separation
using trypsinization techniques makes
reliable recovery of granular layer
keratinocytes more difficult, and this
presumably reflects minimal enrich-
ment of loricrin and filaggrin by
Radoja et al. (2006). Second, trypsini-
zation/brief culture of separated epider-
mal cells can markedly alter gene
transcription profiles (Kennedy-Crispin
et al., 2012). Another consideration is
that melanocytes, located in the basal
epidermis, do not express b4 integrin
and thus are aberrantly included in the
suprabasal fraction by cell separation.
As our study is, to our knowledge, the
first to combine LCM with transcrip-
tional profiling of different epidermal
regions, it provides a unique basis of
comparison for future work that will use
LCM to examine specific cell
populations of various disease states
where the epidermis is undergoing
hyperplastic or neoplastic changes.
Skin biopsies were obtained from
volunteers under a protocol approved
by The Rockefeller University’s Institu-
tional Review Board. Written, informed
consent was obtained from all patients
and the study adhered to the Declara-
tion of Helsinki Principles.
Table 1. Selected transcription factors (identified through Gene Ontology
term 0003700) differentially expressed between basal and suprabasal
epidermis
Gene Description FCH1
Transcription factors upregulated in the basal compared with the suprabasal epidermis
PTTG12 Pituitary tumor-transforming gene 1 10.303
ZNF281 Zinc-finger protein 281 9.241
RFX5 Regulatory factor X5 (influences HLA class II expression) 8.914
SP4 Sp4 transcription factor 6.347
Transcription factors upregulated in the suprabasal compared with the basal epidermis
ARNTL2 Aryl hydrocarbon receptor nuclear translocator-like 2 7.155
SREBF22 Sterol regulatory element–binding transcription factor 2 2.500
Abbreviations: FCH, fold change; HLA, human leukocyte antigen.
1False discovery rate o0.05 for all genes.
2Reported as differentially expressed by Radoja et al. (2006), but not previously confirmed by
immunohistochemistry.
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TO THE EDITOR
Dapsone (4,40-diaminodiphenylsulfone)
has been widely used in the treatment
of leprosy since its discovery in the
1940s, and some of its reported side
effects include methemoglobinemia,
hemolysis, agranulocytosis, and dap-
sone-induced hypersensitivity reactions
(DIHRs) (Zhu and Stiller, 2001). DIHR is
a life-threatening drug reaction, which
has been reported in B2% of leprosy
patients on dapsone therapy; thus, with
12.5% mortality, DIHR is one of the
major causes of mortality in leprosy
patients (Pandey et al., 2007; Shen
et al., 2011). DIHR is clinically mani-
fested through fever, rash, lymphadeno-
pathy, and hepatitis, and is categorized
under the drug-induced hypersensitivity
or drug rash with eosinophilia and
systemic symptoms syndromes (Sener
et al., 2006; Kardaun et al., 2007;
Kumari et al., 2011). Unlike other drug
reactions, DIHR usually presents with
low hemoglobin and a higher risk of
liver involvement, including cholestatic
or hepatocellular disease, or both
(Richardus and Smith, 1989; Zhu and
Stiller, 2001).
Although the exact mechanism of
DIHR remains unclear, numerous
reports have described the associations
between human leukocyte antigens
(HLA, especially MHCI) and drug
eruptions in patients with various dis-
eases (Mallal et al., 2002; Chung et al.,
2004; Pavlos et al., 2012). Some HLA
profiles are useful tools in diagnosing
and preventing life-threatening adverse
drug reactions (Chung et al., 2004;
Mallal et al., 2008). Dapsone is meta-
bolized through acetylation and
N-hydroxylation. Genetic polymorph-
ism of human NAT2 determining slow
acetylator status is a predisposing factor
for allergic diseases and drug adverse
reactions (Zielinska et al., 1998;
Gawronska-Szklarz et al., 1999).
Cytochrome P450 2C9 (CYP2C9) has
also been shown to be the initial step
in the formation of toxic intermediate
metabolites of sulfonamides, which are
analogs of dapsone, that can induce
hemolytic anemia and skin rash (Winter
et al., 2000; Wolkenstein et al., 2005).
We performed a case–control
study from June 2009 to June 2012 in
Southern China and screened 1058
cases of leprosy patients. Among them,
21 cases (1.98%) met the enrollment
criteria for DIHR according to
Richardus and Smith’s (1989) criteria;
105 dapsone-tolerant control cases were
also studied, defined as leprosy patients
with more than 8 weeks of exposure
to dapsone but without any episode of
drug eruption and reaction. In addition,
100 non-leprosy control individuals
were recruited from local community
blood donors. The socio-demographic
characteristics of the DIHR patients,Accepted article preview online 19 April 2013; published online 16 May 2013
Abbreviations: AUC, area under the curve; CYP2C9, cytochrome P450 2C9; DIHR, dapsone-induced
hypersensitivity reaction; HLA, human leukocyte antigen; MHC, major histocompatibility complex; NAT2,
N-acetyltransferase2
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